Syntax Research Inc. Invests $1.23 Million in Abbott Laboratories $ABT

Syntax Research Inc. bought a new stake in shares of Abbott Laboratories (NYSE:ABT) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 12,000 shares of the healthcare product maker’s stock, valued at approximately $1,232,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. MidAtlantic Capital Management Inc. purchased a new position in Abbott Laboratories during the 4th quarter valued at $25,000. Cornerstone Financial Management LLC bought a new stake in shares of Abbott Laboratories during the 4th quarter valued at about $25,000. Purpose Unlimited Inc. purchased a new position in shares of Abbott Laboratories during the fourth quarter valued at about $25,000. Portfolio Resources Advisor Group Inc. bought a new position in Abbott Laboratories in the fourth quarter worth about $26,000. Finally, Abound Financial LLC purchased a new stake in Abbott Laboratories in the fourth quarter worth about $26,000. Institutional investors own 75.18% of the company’s stock.

Insider Buying and Selling

In other news, Director Daniel J. Starks purchased 10,000 shares of Abbott Laboratories stock in a transaction that occurred on Monday, April 27th. The stock was bought at an average price of $92.65 per share, with a total value of $926,500.00. Following the completion of the transaction, the director directly owned 6,751,103 shares of the company’s stock, valued at approximately $625,489,692.95. The trade was a 0.15% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Philip P. Boudreau acquired 2,200 shares of the firm’s stock in a transaction that occurred on Thursday, April 23rd. The stock was purchased at an average price of $91.50 per share, with a total value of $201,300.00. Following the completion of the acquisition, the chief financial officer owned 2,200 shares in the company, valued at $201,300. The trade was a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Corporate insiders own 0.46% of the company’s stock.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Robert W. Baird initiated coverage on Abbott Laboratories with an Outperform rating and a $121 price target, signaling strong upside potential and renewed Wall Street confidence. Article Title
• Positive Sentiment: Tandem Diabetes Care launched compatibility for its t:slim X2 insulin pump with Abbott’s FreeStyle Libre 3 Plus sensor in five international markets, which could expand Abbott’s CGM ecosystem and support diabetes-care sales. Article Title
• Positive Sentiment: Wells Fargo reiterated a Buy rating on Abbott Laboratories, adding to the positive analyst sentiment around the stock. Article Title
• Positive Sentiment: TipRanks highlighted Abbott as one of the dividend aristocrats that Wall Street currently likes, reinforcing the view that it remains a favored defensive healthcare name. Article Title
• Neutral Sentiment: Recent coverage compared Abbott with Intuitive Surgical, but the article was more of a broader healthcare-stock debate than a direct catalyst for Abbott’s shares. Article Title
• Neutral Sentiment: Abbott-related commentary on multi-cancer blood screening and broader healthcare trends is informative for the sector, but it does not appear to be a direct company-specific catalyst. Article Title
• Negative Sentiment: Abbott also faced headlines about a closed U.S. criminal probe into its infant-formula plant and a proposed civil settlement, which could remain a legal overhang even if the worst-case risk has eased. Article Title

Wall Street Analysts Forecast Growth

ABT has been the topic of a number of research analyst reports. Sanford C. Bernstein reduced their target price on Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating on the stock in a report on Friday, April 17th. Weiss Ratings lowered Abbott Laboratories from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Tuesday, June 16th. JPMorgan Chase & Co. reduced their price target on Abbott Laboratories from $123.00 to $110.00 and set an “overweight” rating on the stock in a research note on Friday, April 17th. Citigroup lowered their price objective on Abbott Laboratories from $136.00 to $108.00 and set a “buy” rating for the company in a research report on Friday, April 17th. Finally, BTIG Research restated a “buy” rating and set a $131.00 target price on shares of Abbott Laboratories in a report on Monday, April 27th. Two research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $118.42.

Abbott Laboratories Trading Up 1.6%

NYSE ABT opened at $92.15 on Thursday. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $137.49. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. The stock’s fifty day moving average price is $88.83 and its 200-day moving average price is $104.62. The stock has a market cap of $160.51 billion, a P/E ratio of 25.81, a P/E/G ratio of 1.56 and a beta of 0.61.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.14 by $0.01. The firm had revenue of $11.16 billion during the quarter, compared to analyst estimates of $10.99 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.Abbott Laboratories’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, equities analysts forecast that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be paid a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 2.7%. The ex-dividend date is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio is currently 70.59%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.